肾移植等待状态与ISCHEMIA-CKD试验结局
ISCHEMIA-CKD事后分析比较了肾移植等待名单患者与非等待患者按管理策略的结局。777例慢性冠脉综合征伴至少中度缺血患者中194例(25%)在等待名单。等待组 versus 非等待组侵入策略的主要结局校正HR分别为0.91(95%CI 0.54-1.54)和1.03(95%CI 0.78-1.37)。结论:侵入策略未改善等待肾移植患者的结局。
要点
- 肾移植等待患者接受侵入策略未改善主要或次要结局。
- 数据不支持对晚期CKD合并慢性冠脉综合征等待移植者常规冠脉造影或血运重建。
- 等待与非等待组间随机治疗效应无显著异质性。
核心结论
- 在ISCHEMIA-CKD中,肾移植候选者接受侵入策略与保守管理相比未改善结局。
- 数据不支持对晚期CKD合并慢性冠脉综合征且等待移植的患者常规行冠脉造影或血运重建。
研究设计与样本
- ISCHEMIA-CKD试验的事后分析,共777例慢性冠脉综合征伴至少中度缺血患者。
- 194例(25%)在肾移植等待名单,比较等待与非等待组按管理策略的结局。
- 主要和次要结局采用Cox多变量模型分析,并评估随机治疗效应的异质性。
主要发现
- 等待组与非等待组相比更年轻(60岁 vs 65岁),亚洲种族比例更低(15% vs 29%),透析比例更高(83% vs 44%),心绞痛症状更少。
- 等待组接受侵入策略 versus 保守策略的主要结局校正HR为0.91(95%CI 0.54-1.54),非等待组为1.03(95%CI 0.78-1.37),交互作用P=0.68。
- 次要结局校正HR在等待组为0.89(95%CI 0.55-1.46),非等待组为1.17(95%CI 0.89-1.53),交互作用P=0.35。
临床怎么用
- 对于晚期CKD合并慢性冠脉综合征且等待肾移植的患者,不应仅因等待移植而常规行冠脉造影或血运重建。
- 侵入策略在该人群中未显示优于保守管理的结局,临床决策应个体化。
局限性
- 为事后分析,非随机比较等待与非等待组,可能存在残余混杂。
- 等待组与非等待组基线特征差异明显(如年龄、种族、透析状态、症状)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with chronic kidney disease (CKD) and coronary artery disease frequently undergo preemptive revascularization before kidney transplant listing. OBJECTIVES: In this post hoc analysis from ISCHEMIA-CKD (International Study of Comparative Health Effectiveness of Medical and Invasive Approaches-Chronic Kidney Disease), we compared outcomes of patients not listed versus those listed according to management strategy. METHODS: In the ISCHEMIA-CKD trial (n = 777), 194 patients (25%) with chronic coronary syndromes and at least moderate ischemia were listed for transplant. The primary (all-cause mortality or nonfatal myocardial infarction) and secondary (death, nonfatal myocardial infarction, hospitalization for unstable angina, heart failure, resuscitated cardiac arrest, or stroke) outcomes were analyzed using Cox multivariable modeling. Heterogeneity of randomized treatment effect between listed versus not listed groups was assessed. RESULTS: Compared with those not listed, listed patients were younger (60 years vs 65 years), were less likely to be of Asian race (15% vs 29%), were more likely to be on dialysis (83% vs 44%), had fewer anginal symptoms, and were more likely to have coronary angiography and coronary revascularization irrespective of treatment assignment. Among patients assigned to an invasive strategy versus conservative strategy, the adjusted hazard ratios for the primary outcome were 0.91 (95% confidence interval [CI]: 0.54-1.54) and 1.03 (95% CI: 0.78-1.37) for those listed and not listed, respectively (pinteraction= 0.68). Adjusted hazard ratios for secondary outcomes were 0.89 (95% CI: 0.55-1.46) in listed and 1.17 (95% CI: 0.89-1.53) in those not listed (pinteraction = 0.35). CONCLUSIONS: In ISCHEMIA-CKD, an invasive strategy in kidney transplant candidates did not improve outcomes compared with conservative management. These data do not support routine coronary angiography or revascularization in patients with advanced CKD and chronic coronary syndromes listed for transplant. (ISCHEMIA-Chronic Kidney Disease Trial [ISCHEMIA-CKD]; NCT01985360).
引用
- Herzog CA, Simegn MA, Xu Y, et al. Kidney Transplant List Status and Outcomes in the ISCHEMIA-CKD Trial. J Am Coll Cardiol. 2021. PMID: 33989711. doi:10.1016/j.jacc.2021.05.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。